Русский
Risk factors for SARS-CoV-2 infection and peculiarities of viral shedding in patients with sarcoidosis
DOI: https://dx.doi.org/10.18565/epidem.2022.12.2.83-6
Dobin V.L., Panin I.V., Martynov V.A.
Academician I.P. Pavlov Ryazan State Medical University, Ministry of Health of Russia, Ryazan, Russia
Subjects and methods. Nineteen case histories of S patients who had fallen ill with COVID-19 were analyzed. The diagnosis of S was confirmed morphologically, whereas COVID-19 was confirmed mainly by positive PCR tests for SARS-CoV-2 RNA. Mediastinal, pulmonary-and-mediastinal, and pulmonary S were diagnosed in 11, 6, and 2 cases, respectively. Sixteen patients with S before COVID-19 had a stable clinical condition that required no medical support. In unstable S, 1 patient took azathioprine (100 mg/day) and two had metypred (8 mg/day). As a result of treatment, all the patients with S recovered from COVID-19. All the 19 patients underwent an epidemiological analysis that included an assessment of the likely sources of SARS-CoV-2.
Results. The patients with S were found to have contacts for coronavirus: familial (n = 8), working (n = 6), nosocomial (n = 3), household (n = 1), and unidentified (n = 1) contacts. The mean duration of viral shedding was 10.6±2.8 days in the S patients. Six patients with S had mild COVID-19; 13 had a moderate course with recovery.
Conclusion. The main risk factors for SARS-CoV-2 infection in S are familial and working contacts: being in the same room with the source of infection and professional activities associated with numerous contacts with a large number of people. COVID-19 in S patients was characterized by its mild and moderate clinical course. The mean duration of viral shedding in this case was 10.6±2.8 days.
Literature
1. Добин В.Л., Панин И.В. Саркоидоз и COVID-19. Туберкулез и болезни легких 2021; 99 (8): 7–12. doi.org/10.21292/2075-1230-2021-99-8-7-12 Dobin V.L., Panin I.V. [Sarcoidosis and COVID-19]. Tuberculosis and lung disease 2021; 99 (8): 7–12. (In Russ.). doi.org/10.21292/2075-1230-2021-99-8-7-12 2. Визель А.А., Визель И.Ю., Костинов М.Л., Амиров Н.Б. Саркоидоз. Новая инфекция COVID-19 и вопросы вакцинации. Вестник современной клинической медицины 2021; 14 (4): 48–57. DOI: 10.20969/VKSM.2021.14(4).48-57 Vizel’ A.A., Vizel’ I.Ju., Kostinov M.L., Amirov N.B. [Sarcoidosis. New COVID-19 infection and vaccination issues]. Bulletin of modern clinical medicine 2021; 14 (4): 48–57. (In Russ.). DOI: 10.20969/VKSM.2021.14(4).48-57 3. Manansala M., Ascoli C., Alburquerque A.G., Perkins D., Mirsaedi M., Finn P., Sweiss N.J. Case Series: COVID-19 in African American Patients With Sarcoidosis. Front Med. (Lausanne) 2020; (7): 588527. doi: 10.3389/fmed.2020.588527. PMID: 33251236;PMCID: PMC767220 4. Morgenthau A.S., Levin M.A., Freeman R., Reich D.L., Klang E. Moderate or Severe Impairment in Pulmonary Function is Associated with Mortality in Sarcoidois Patients Infected with SARS-CoV-2. Lung 2020; 198 (5): 771–5. doi: 10.1007/s00408-020-00392-9 5. Baughman R.P., Buchanon M., Rottoli P. et al. Risk and outcome of COVID-19 infection in sarcoidosis patients: results of a self-reporting questionnaire. Sarcoidosis Vasc Lung Dis. 2020; 37: e2020009. doi: 10.36141/svdld.v37i4.10726 6. Sweiss N.J., Korsten P., Syed H.J., Syed Aamer, Culver D.A., Sosenko T. et al. When the game changes: guidance to adjust sarcoidosis management during the COVID-19 pandemic. Chest 2020; 158 (3). doi: 10.1016/j.chest.2020.04.033
About the Autors
Vitaly L. Dobin, MD, Professor, Department of Infectious Diseases and Phthisiology, Academician I.P. Pavlov Ryazan State Medical University, Ministry of Health of Russia, Ryazan, Russia; viladob@gmail.com; http://orcid.org/0000-0003-1946-5193; SPIN 2955-6303
Ilya V. Panin, Cand. Med. Sci., Assistant Professor, Department of Cardiovascular, X-Ray Endovascular Surgery and Radiodiagnosis, Academician I.P. Pavlov Ryazan State Medical University, Ministry of Health of Russia, Ryazan, Russia; iliavpanin@gmail.com; https://orcid.org/0000-0003-1259-1963; SPIN 7597-6703
Professor Vladimir A. Martynov, MD, Head, Department of Infectious Diseases and Phthisiology, Academician I.P. Pavlov Ryazan State Medical University, Ministry of Health of Russia, Ryazan, Russia; dr.martinov@mail.ru; https://orcid.org/0000-0002-0117-0613; SPIN 2378-4380
Similar Articles
